This Article OPEN ACCESS ARTICLE Full Text (PDF) All Versions of this Article: gr.3437105v1 15/7/928    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Loots, G. G. Articles by Rubin, E. M. Search for Related Content PubMed PubMed Citation Articles by Loots, G. G. Articles by Rubin, E. M. Pubmed/NCBI databases Gene GEO Profiles HomoloGene OMIM UniGene Social Bookmarking                   What's this?

Letter

Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease

¹ Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA , ² Novartis Institutes for BioMedical Research, Bone and Cartilage, Basel, Switzerland , ³ DOE, Joint Genome Institute, Walnut Creek, California 94598, USA , ⁴ Genome Biology Division, Lawrence Livermore Laboratory, Livermore, California 94550, USA

Mutations in distant regulatory elements can have a negative impact on human development and health, yet because of the difficulty of detecting these critical sequences, we predominantly focus on coding sequences for diagnostic purposes. We have undertaken a comparative sequence-based approach to characterize a large noncoding region deleted in patients affected by Van Buchem (VB) disease, a severe sclerosing bone dysplasia. Using BAC recombination and transgenesis, we characterized the expression of human sclerostin (SOST) from normal (SOST^wt) or Van Buchem (SOST^vb) alleles. Only the SOST^wt allele faithfully expressed high levels of human SOST in the adult bone and had an impact on bone metabolism, consistent with the model that the VB noncoding deletion removes a SOST-specific regulatory element. By exploiting cross-species sequence comparisons with in vitro and in vivo enhancer assays, we were able to identify a candidate enhancer element that drives human SOST expression in osteoblast-like cell lines in vitro and in the skeletal anlage of the embryonic day 14.5 (E14.5) mouse embryo, and discovered a novel function for sclerostin during limb development. Our approach represents a framework for characterizing distant regulatory elements associated with abnormal human phenotypes.

Article and publication are at http://www.genome.org/cgi/doi/10.1101/gr.3437105. Article published online before print in June 2005.

⁵ Corresponding author.
E-mail loots1{at}llnl.gov; fax (925) 422-2099.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				A. G. Robling, P. J. Niziolek, L. A. Baldridge, K. W. Condon, M. R. Allen, I. Alam, S. M. Mantila, J. Gluhak-Heinrich, T. M. Bellido, S. E. Harris, et al. Mechanical Stimulation of Bone in Vivo Reduces Osteocyte Expression of Sost/Sclerostin J. Biol. Chem., February 29, 2008; 283(9): 5866 - 5875. [Abstract] [Full Text] [PDF]

				P. t. Dijke, C. Krause, D. J. J. de Gorter, C. W.G.M. Lowik, and R. L. van Bezooijen Osteocyte-Derived Sclerostin Inhibits Bone Formation: Its Role in Bone Morphogenetic Protein and Wnt Signaling J. Bone Joint Surg. Am., February 1, 2008; 90(Supplement_1): 31 - 35. [Abstract] [Full Text] [PDF]

				E. CANALIS Nephroblastoma Overexpressed (Nov) Is a Novel Bone Morphogenetic Protein Antagonist Ann. N.Y. Acad. Sci., November 1, 2007; 1116(1): 50 - 58. [Abstract] [Full Text] [PDF]

				E. Canalis, A. Giustina, and J. P. Bilezikian Mechanisms of Anabolic Therapies for Osteoporosis N. Engl. J. Med., August 30, 2007; 357(9): 905 - 916. [Full Text] [PDF]

				X. Long and J. M. Miano Remote Control of Gene Expression J. Biol. Chem., June 1, 2007; 282(22): 15941 - 15945. [Abstract] [Full Text] [PDF]

				H. Kikuta, M. Laplante, P. Navratilova, A. Z. Komisarczuk, P. G. Engstrom, D. Fredman, A. Akalin, M. Caccamo, I. Sealy, K. Howe, et al. Genomic regulatory blocks encompass multiple neighboring genes and maintain conserved synteny in vertebrates Genome Res., May 1, 2007; 17(5): 545 - 555. [Abstract] [Full Text] [PDF]

				D. J. Samuelson, S. E. Hesselson, B. A. Aperavich, Y. Zan, J. D. Haag, A. Trentham-Dietz, J. M. Hampton, B. Mau, K.-S. Chen, C. Baynes, et al. Rat Mcs5a is a compound quantitative trait locus with orthologous human loci that associate with breast cancer risk PNAS, April 10, 2007; 104(15): 6299 - 6304. [Abstract] [Full Text] [PDF]

				N. Sabherwal, F. Bangs, R. Roth, B. Weiss, K. Jantz, E. Tiecke, G. K. Hinkel, C. Spaich, B. P. Hauffa, H. van der Kamp, et al. Long-range conserved non-coding SHOX sequences regulate expression in developing chicken limb and are associated with short stature phenotypes in human patients Hum. Mol. Genet., January 15, 2007; 16(2): 210 - 222. [Abstract] [Full Text] [PDF]

				S. H. Ralston and B. de Crombrugghe Genetic regulation of bone mass and susceptibility to osteoporosis Genes & Dev., September 15, 2006; 20(18): 2492 - 2506. [Abstract] [Full Text] [PDF]

				R. L. van Bezooijen, S. E. Papapoulos, N. A. Hamdy, P. ten Dijke, and C. W. Lowik Control of Bone Formation by Osteocytes? Lessons from the Rare Skeletal Disorders Sclerosteosis and van Buchem Disease IBMS BoneKEy, December 1, 2005; 2(12): 33 - 38. [Full Text] [PDF]

				L. Flaherty, B. Herron, and D. Symula Genomics of the future: Identification of quantitative trait loci in the mouse Genome Res., December 1, 2005; 15(12): 1741 - 1745. [Abstract] [Full Text] [PDF]